IBRX Q3 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M+425.1% YoY

Gross Profit

$28M87.1% margin

Operating Income

-$56M-173.5% margin

Net Income

-$67M-209.8% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+21.3%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$519M

Total Liabilities

$1.0B

Stockholders' Equity

-$524M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$6M	+425.1%
Gross Profit	$28M	$6M	+357.5%
Operating Income	-$56M	-$80M	+30.7%
Net Income	-$67M	-$86M	+21.6%

Revenue Segments

Product

$32M99%

Product and Service, Other

$281,0001%

Geographic Segments

UNITED STATES

$32M99%

Europe

$262,0001%